Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Kiadis Pharma |
---|---|
Information provided by: | Kiadis Pharma |
ClinicalTrials.gov Identifier: | NCT00248365 |
The purpose of this study is to assess the tolerability and safety of two intensity levels of Theralux extracorporeal photochemotherapy in the treatment of subjects with steroid refractory or intolerant GvHD.
The current hypothesis is that apoptotic cells re-injected into patients induce an immunomodulation effect alleviating the GvHD symptoms. Using the Theralux procedure, the dose of photodynamic treatment may be modulated to achieve the maximal immunomodulatory effects in the treated patients.
The intervention is iterative extracorporeal photochemotherapy of autologous peripheral blood mononuclear cells (PBMC) with a rhodamine-derivative TH9402 (drug) and Theralux (device).
Condition | Intervention | Phase |
---|---|---|
Graft vs Host Disease |
Procedure: Theralux extracorporeal photochemotherapy |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety, Biological and Clinical Efficacy of Two Intensity Levels of Theralux Extracorporeal Photochemotherapy in Subjects With Extensive Chronic GvHD Refractory or Intolerant to Standard Therapy: A Randomized, Open-Label Phase I/II Clinical Trial |
Enrollment: | 20 |
Study Start Date: | November 2005 |
Study Completion Date: | August 2007 |
Graft versus host disease (GvHD) remains a major cause of morbidity and mortality related to allogeneic stem cell transplantation. While improvements in immuno-suppressive regimens have reduced the frequency and severity of acute GvHD, the incidence of chronic GvHD (cGvHD) remains unchanged ranging from 30% after sibling matched related donor transplants to over 70% after unrelated donor bone marrow or peripheral blood stem cell transplant. Factors associated with cGvHD include increased donor and recipient age, prior acute GvHD, and the use of alloimmune female donors. Conventional therapeutic approaches for cGvHD, including corticosteroids and immunosuppressive agents, have demonstrated limited efficacy in patients with extensive disease and are associated with high toxicity.
Iterative extracorporeal photopheresis has demonstrated clinical and immunomodulatory activity in subjects with acute and chronic GvHD. The currently available process of ECP has not been controlled for cell number, exposure time, or specific cell populations targeted due to the nature of the procedure. Using the Theralux procedure, defined populations of cells may be targeted, and the intensity of photoactivating agent and exposure can be modulated to achieve the maximal immunomodulatory effects in the treated subjects. This study will attempt to explore the effects of the Theralux procedure under two defined conditions. Response and toxicity will be determined at each intensity level and the dose associated with clinical response and immunomodulatory effects on DC and NK cell populations will be defined as the optimal intensity level for subsequent larger trials.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, British Columbia | |
B.C. Cancer Research Center | |
Vancouver, British Columbia, Canada, V5Z 1L3 | |
Canada, Ontario | |
Ottawa General Hospital | |
Ottawa, Ontario, Canada, K1H 8L6 | |
McMaster University Medical Center | |
Hamilton, Ontario, Canada, L8N 3Z5 | |
Canada, Quebec | |
Maisonneuve-Rosemont Hospital | |
Montreal, Quebec, Canada, H1T 2M4 |
Study ID Numbers: | CR-ECP-001 |
Study First Received: | November 3, 2005 |
Last Updated: | January 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00248365 |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
Chronic GvHD Extensive chronic GvHD Resistant chronic GvHD |
Graft versus host disease Graft vs Host Disease Homologous wasting disease |
Immune System Diseases |